Neuphoria Therapeutics Inc. (NEUP) Comparison with companies in other sectors?

Neuphoria Therapeutics Inc. has a share price of 1.88M. You can analyze Neuphoria Therapeutics Inc. (NEUP) competitors across different market sectors through stock heatmaps.

What are NEUP's NET and operating margins?

Neuphoria Therapeutics Inc. (NEUP) operating margin is around 0.15, and net profit margin is approximately 0.37 as of the latest reports.

In what way does NEUP's earnings per share (EPS) trend reflect its financial momentum?

Neuphoria Therapeutics Inc. (NEUP) EPS is 18.83 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Neuphoria Therapeutics Inc. is 0.45, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Neuphoria Therapeutics Inc.?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Neuphoria Therapeutics Inc. like P/E which is 346.44, P/B which is 76.44, and PEG which is 2.74. Compare them with sector averages to evaluate if the stock is priced fairly.

Neuphoria Therapeutics Inc.

NEUP•NASDAQ

Healthcare

Medical - Pharmaceuticals

$8.50

$0.10(1.19%)

Fundamental Analysis of Neuphoria Therapeutics Inc. (NEUP)

Comprehensive financial metrics and ratios analysis

EPS (TTM)

$18.83

P/E Ratio

0.45

ROE

0.31%

Net Margin

0.37%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$15.98M

Shares OutstandingTotal number of shares issued

$1.88M

Book Value/ShareNet worth per share

$0.11

Revenue/ShareAnnual revenue per share

$0.07

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$18.83

Net MarginNet income as percentage of revenue

36.62%

Operating MarginOperating income as percentage of revenue

14.76%

ROEReturn on shareholders' equity

30.88%

ROAReturn on total assets

18.67%

ROCEReturn on capital employed

7.93%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$0.002

Cash/ShareCash and equivalents per share

$0.07

FCF YieldFree cash flow as percentage of market cap

2.60%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for NEUPFinancial Ratios Analysis details for NEUP are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for NEUPSector Benchmarking details for NEUP are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Neuphoria Therapeutics Inc. Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Neuphoria Therapeutics Inc.. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Neuphoria Therapeutics Inc.'s unique business strengths and challenges.

Key Financial Metrics for Neuphoria Therapeutics Inc.

For Neuphoria Therapeutics Inc., essential financial indicators include EPS 18.83, PE 0.45, and ROE 0.31. These key ratios reveal insights into Neuphoria Therapeutics Inc.'s profitability, valuation, and operational health. Understanding these metrics enables you to compare Neuphoria Therapeutics Inc. with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Neuphoria Therapeutics Inc.

Metrics like Net Margin 36.62% and ROA 18.67% shed light on how well Neuphoria Therapeutics Inc. is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Neuphoria Therapeutics Inc. can sustain its operations and continue growing in the future.

Valuation and Market Position of Neuphoria Therapeutics Inc.

Using ratios such as P/B Ratio 76.44 and PEG Ratio 2.74, investors can assess whether Neuphoria Therapeutics Inc. is appropriately valued based on its financials and growth potential. These figures, combined with Neuphoria Therapeutics Inc.'s market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Neuphoria Therapeutics Inc.

Financial health indicators, such as Debt/Equity Ratio 0.007 and Cash Flow $0.002, provide a snapshot of Neuphoria Therapeutics Inc.'s ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Neuphoria Therapeutics Inc., is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Neuphoria Therapeutics Inc.

Investing in Neuphoria Therapeutics Inc. based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Neuphoria Therapeutics Inc. focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;